Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
25 May 2023
25 May 2023
Historique:
received:
23
01
2023
accepted:
12
05
2023
medline:
26
5
2023
pubmed:
26
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
The identification of BRAF V600 mutation in multiple cancers beyond melanoma and the development of combined BRAF and MEK targeting agents have altered the landscape of tissue-agnostic precision oncology therapies with an impact on survival outcomes. Despite initial efficacy, resistance emerges, and it is pertinent to identify putative resistance mechanisms. We report a case of recurrent glioblastoma (GBM) harboring BRAF V600E alteration who initially responded to combined BRAF + MEK inhibition and subsequently developed treatment resistance by histological transformation to gliosarcoma and acquisition of oncogenic KRAS
Identifiants
pubmed: 37231247
doi: 10.1038/s41698-023-00398-5
pii: 10.1038/s41698-023-00398-5
pmc: PMC10212928
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47Subventions
Organisme : U.S. Department of Health & Human Services | NIH | NIH Clinical Center (Clinical Center)
ID : R01CA273168
Organisme : U.S. Department of Health & Human Services | NIH | NIH Clinical Center (Clinical Center)
ID : R01CA242845
Informations de copyright
© 2023. The Author(s).
Références
Clin Cancer Res. 2021 Nov 15;27(22):6197-6208
pubmed: 34433654
J Thorac Oncol. 2018 Dec;13(12):e249-e251
pubmed: 30467046
BMC Cancer. 2017 Jan 5;17(1):10
pubmed: 28056859
Cancer Treat Rev. 2017 Sep;59:117-122
pubmed: 28806542
Front Oncol. 2022 Dec 13;12:1031378
pubmed: 36582791
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
AJNR Am J Neuroradiol. 2020 Jan;41(1):10-20
pubmed: 31857322
Cancer Discov. 2020 May;10(5):657-663
pubmed: 32029534
J Clin Med. 2022 Mar 05;11(5):
pubmed: 35268520
Acta Neuropathol. 2004 Dec;108(6):467-70
pubmed: 15517309
Trends Cancer. 2020 Sep;6(9):797-810
pubmed: 32540454
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Front Oncol. 2021 Nov 03;11:772052
pubmed: 34804975
Ann Oncol. 2022 Apr;33(4):406-415
pubmed: 35026411
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
J Natl Compr Canc Netw. 2019 May 1;17(5):409-413
pubmed: 31085763
Lancet Oncol. 2022 Jan;23(1):53-64
pubmed: 34838156
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Cancer J. 2012 Mar-Apr;18(2):124-31
pubmed: 22453012
Int J Cancer. 2016 Feb 15;138(4):881-90
pubmed: 26314551
Cancer Cell. 2010 Dec 14;18(6):683-95
pubmed: 21156289
Lancet Oncol. 2020 Sep;21(9):1234-1243
pubmed: 32818466
Front Oncol. 2019 Dec 17;9:1425
pubmed: 31921679